Generic Tyzavan Availability
Last updated on Aug 6, 2025.
Tyzavan is a brand name of vancomycin, approved by the FDA in the following formulation(s):
TYZAVAN (vancomycin hydrochloride - solution;intravenous)
-
Manufacturer: HIKMA
Approval date: February 15, 2019
Strength(s): EQ 1GM BASE/200ML (EQ 5MG BASE/ML) [RLD], EQ 1.5GM BASE/300ML (EQ 5MG BASE/ML) [RLD], EQ 2GM BASE/400ML (EQ 5MG BASE/ML) [RLD], EQ 500MG BASE/100ML (EQ 5MG BASE/ML) [RLD] -
Manufacturer: HIKMA
Approval date: May 13, 2020
Strength(s): EQ 1.25GM BASE/250ML (EQ 5MG BASE/ML) [RLD], EQ 1.75GM BASE/350ML (EQ 5MG BASE/ML) [RLD], EQ 750MG BASE/150ML (EQ 5MG BASE/ML) [RLD]
Is there a generic version of Tyzavan available?
No. There is currently no therapeutically equivalent version of Tyzavan available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Tyzavan. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Glycopeptide compositions
Patent 10,039,804
Issued: August 7, 2018
Inventor(s): Jasprica Ivona & Keser Sabina & Pindric Katarina
Assignee(s): XELLIA PHARMACEUTICALS APSSolutions comprising a glycopeptide antibiotic, for example Vancomycin, and an amino acid or amino acid derivative such as N-acetyl-Glycine or N-acetyl-D-Alanine are provided. These solutions are stable or stabilized for long-term periods at conditions of normal use and storage, and can be formulated as pharmaceutical solutions for use in subjects. Methods of manufacturing and using these solutions are also provided, as are methods of stabilizing a glycopeptide antibiotic, for example Vancomycin, using amino acids or amino acid derivatives such as N-acetyl-Glycine or N-acetyl-D-Alanine.
Patent expiration dates:
- November 6, 2035✓✓
- November 6, 2035
-
Glycopeptide compositions
Patent 10,188,697
Issued: January 29, 2019
Inventor(s): Jasprica Ivona & Keser Sabina & Pindric Katarina
Assignee(s): XELLIA PHARMACEUTICALS APSSolutions comprising a glycopeptide antibiotic, for example Vancomycin, and an amino acid or amino acid derivative such as N-acetyl-Glycine or N-acetyl-D-Alanine are provided. These solutions are stable or stabilized for long-term periods at conditions of normal use and storage, and can be formulated as pharmaceutical solutions for use in subjects. Methods of manufacturing and using these solutions are also provided, as are methods of stabilizing a glycopeptide antibiotic, for example Vancomycin, using amino acids or amino acid derivatives such as N-acetyl-Glycine or N-acetyl-D-Alanine.
Patent expiration dates:
- November 6, 2035✓✓
- November 6, 2035
-
Glycopeptide compositions
Patent 10,849,956
Issued: December 1, 2020
Inventor(s): Jasprica; Ivona et al.
Assignee(s): Xellia Pharmaceuticals APS (N/A, N/A)Solutions comprising a glycopeptide antibiotic, for example Vancomycin, and an amino acid or amino acid derivative such as N-acetyl-Glycine or N-acetyl-D-Alanine are provided. These solutions are stable or stabilized for long-term periods at conditions of normal use and storage, and can be formulated as pharmaceutical solutions for use in subjects. Methods of manufacturing and using these solutions are also provided, as are methods of stabilizing a glycopeptide antibiotic, for example Vancomycin, using amino acids or amino acid derivatives such as N-acetyl-Glycine or N-acetyl-D-Alanine.
Patent expiration dates:
- November 6, 2035✓
- November 6, 2035
-
Glycopeptide compositions
Patent 11,517,609
Issued: December 6, 2022
Inventor(s): Jasprica Ivona & Keser Sabina & Pindric Katarina
Assignee(s): Xellia Pharmaceuticals ApSSolutions comprising a glycopeptide antibiotic, for example Vancomycin, and an amino acid or amino acid derivative such as N-acetyl-Glycine or N-acetyl-D-Alanine are provided. These solutions are stable or stabilized for long-term periods at conditions of normal use and storage, and can be formulated as pharmaceutical solutions for use in subjects. Methods of manufacturing and using these solutions are also provided, as are methods of stabilizing a glycopeptide antibiotic, for example Vancomycin, using amino acids or amino acid derivatives such as N-acetyl-Glycine or N-acetyl-D-Alanine.
Patent expiration dates:
- November 6, 2035✓
- November 6, 2035
-
Glycopeptide compositions
Patent 11,628,200
Issued: April 18, 2023
Inventor(s): Jasprica; Ivona et al.
Assignee(s): XELLIA PHARMACEUTICALS APS (Copenhagen, DK)Solutions comprising a glycopeptide antibiotic, for example Vancomycin, and an amino acid or amino acid derivative such as N-acetyl-Glycine or N-acetyl-D-Alanine are provided. These solutions are stable or stabilized for long-term periods at conditions of normal use and storage, and can be formulated as pharmaceutical solutions for use in subjects. Methods of manufacturing and using these solutions are also provided, as are methods of stabilizing a glycopeptide antibiotic, for example Vancomycin, using amino acids or amino acid derivatives such as N-acetyl-Glycine or N-acetyl-D-Alanine.
Patent expiration dates:
- November 6, 2035✓
- November 6, 2035
-
Glycopeptide compositions
Patent 12,161,690
Issued: December 10, 2024
Inventor(s): Jasprica; Ivona et al.
Assignee(s): Hikma Pharmaceuticals USA Inc. (Berkeley Heights, NJ)Solutions comprising a glycopeptide antibiotic, for example Vancomycin, and an amino acid or amino acid derivative such as an N-acetyl amino acid are provided. These solutions are stable or stabilized for long-term periods at conditions of normal use and storage, and can be formulated as pharmaceutical solutions for use in subjects. Methods of manufacturing and using these solutions are also provided, as are methods of stabilizing a glycopeptide antibiotic, for example Vancomycin, using amino acids or amino acid derivatives such as N-acetyl amino acids.
Patent expiration dates:
- November 6, 2035✓
- November 6, 2035
More about Tyzavan (vancomycin)
- Check interactions
- Compare alternatives
- Latest FDA alerts (6)
- Dosage information
- During pregnancy
- Drug class: glycopeptide antibiotics
- Breastfeeding
Patient resources
Other brands
Vancocin, Firvanq, Vancocin HCl, Vancocin HCl Pulvules
Professional resources
Other brands
Related treatment guides
Related/similar drugs
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.